SynthesisPLoS neglected tropical diseases2022
Global prevalence and case fatality rate of Enterovirus D68 infections, a systematic review and meta-analysis.
Synthesis in PLoS neglected tropical diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 37 citations in OpenAlex.
- Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity.Nature reviews. Cancer · 2026Review
- Molecular surveillance and genomic characterization of enterovirus D68 in southern Portugal, 2024-2025.Archives of virology · 2026Article
- Molecular detection of endemic coronaviruses and enterovirus D68 in respiratory samples from 2016 in Panama: a retrospective study.Virology journal · 2026Article
- Clinical Insights and Severity of Enterovirus D68 Respiratory Infections in Vietnamese Children.Open forum infectious diseases · 2026Article
- Molecular characterization of enteroviruses in patients with acute respiratory infection and influenza-like illness in the Central African Republic revealed mainly polioviruses and other enteric enterovirus types.Access microbiology · 2026Article
- Respiratory enterovirus D68: virology, clinical surveillance, host-pathogen interactions, and therapeutic prospects.Frontiers in cellular and infection microbiology · 2026Review
- ARRDC3 promotes lysosome-mediated YAP degradation to inhibit enterovirus replication.Virologica Sinica · 2025Article
- Design of a Fluorescence Polarization Probe for Enterovirus 2C Proteins.Journal of medicinal chemistry · 2025Article
- Enhanced genomic surveillance of enteroviruses reveals a surge in enterovirus D68 cases, the Johns Hopkins health system, Maryland, 2024.Journal of clinical microbiology · 2025Article
- The use of sialic acids as attachment factors is a common feature ofJournal of virology · 2025Article
- Clinical presentation of Enterovirus D68 in adults with acute respiratory infections consulting in emergency departments in Quebec, Canada.IJID regions · 2025Article
- Acute flaccid myelitis in Europe between 2016 and 2023: indicating the need for better registration.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Article
- Direct amplification and sequencing of enterovirus genomes from clinical and wastewater samples reveals uncommon virus types in Cameroon.Archives of virology · 2025Article
- Hidden in plain sight: the impact of human rhinovirus infection in adults.Respiratory research · 2025Review
- Enteroviral 3C protease cleaves N4BP1 to impair the host inflammatory response.Journal of virology · 2025Article
- Article
- Discovery of A-967079 as an Enterovirus D68 Antiviral by Targeting the Viral 2C Protein.ACS infectious diseases · 2024Article
- Caspase-8 activation regulates enterovirus D68 infection-induced inflammatory response and cell death.Biosafety and health · 2024Article
- Pan-Enterovirus Characterization Reveals Cryptic Circulation of Clinically Relevant Subtypes in Arizona Wastewater.medRxiv : the preprint server for health sciences · 2024Article
- Acute flaccid myelitis in low- to middle-income countries: diagnosis and surveillance.Brain communications · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors at 9 institutions in 3 countries.
Funding
Abstract
A substantial amount of epidemiological data has been reported on Enterovirus D68 (EV-D68) infections after the 2014 outbreak. Our goal was to map the case fatality rate (CFR) and prevalence of current and past EV-D68 infections. We conducted a systematic review (PROSPERO, CRD42021229255) with published articles on EV-68 infections in PubMed, Embase, Web of Science and Global Index Medicus up to January 2021. We determined prevalences using a model random effect. Of the 4,329 articles retrieved from the databases, 89 studies that met the inclusion criteria were from 39 different countries with apparently healthy individuals and patients with acute respiratory infections, acute flaccid myelitis and asthma-related diseases. The CFR estimate revealed occasional deaths (7/1353) related to EV-D68 infections in patients with severe acute respiratory infections. Analyses showed that the combined prevalence of current and past EV-D68 infections was 4% (95% CI = 3.1-5.0) and 66.3% (95% CI = 40.0-88.2), respectively. The highest prevalences were in hospital outbreaks, developed countries, children under 5, after 2014, and in patients with acute flaccid myelitis and asthma-related diseases. The present study shows sporadic deaths linked to severe respiratory EV-D68 infections. The study also highlights a low prevalence of current EV-D68 infections as opposed to the existence of EV-D68 antibodies in almost all participants of the included studies. These findings therefore highlight the need to implement and/or strengthen continuous surveillance of EV-D68 infections in hospitals and in the community for the anticipation of the response to future epidemics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.